Jinxin Reproduction (01951) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
The Zhitong Finance App learned that Jinxin Reproduction (01951) rose more than 6%. As of press release, it had risen 6.17% to HK$2.58, with a turnover of HK$29.36,500.
According to the news, starting April 1, the Shandong Assisted Reproduction Medical Service Program was officially included in medical insurance. Furthermore, according to recent news from the National Health Insurance Administration, the four provinces of Beijing, Guangxi, Inner Mongolia, and Gansu have successively included assisted reproduction in medical insurance reimbursement. Northeast Securities previously stated that relevant policies are expected to be promoted nationwide, accessibility to assisted reproduction will increase, and private assisted reproduction institutions are expected to benefit.
Furthermore, on April 1, Jinxin Fertility announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia.